Skip to main content

Advertisement

SpringerLink
Log in

Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?

  • Gastrointestinal Cancers (B Czito, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Pancreatic adenocarcinoma represents a significant cause of morbidity and mortality in the modern era. Despite advances in the management of unresectable and advanced disease, the only potential avenue for cure at this time is resection. As our radiographic and surgical techniques have improved, we are better able to select patients who are the best candidates for a margin-negative resection, with or without the use of preoperative therapy. There is an emerging consensus on the definition of borderline resectable pancreatic cancer, but much work still needs to be done given the heterogeneous patient population, intervention, and outcome metrics used in previous retrospective and prospective studies. When designing future prospective trials of novel preoperative approaches, standardization of the stage of disease for the study population is essential to allow for accurate interpretation of study results. Ultimately, to make significant progress in localized pancreatic cancer, we urgently need effective novel therapeutic agents used in an optimal sequence with surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Paper of particular interest, published recently, have been noted as • Of importance •• Of major importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.

    Article  PubMed  Google Scholar 

  2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57. doi:10.1016/S0140-6736(04)15841-8.

    Article  CAS  PubMed  Google Scholar 

  3. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621–33.

    Article  CAS  PubMed  Google Scholar 

  4. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37. doi:10.1056/NEJMsa012337.

    Article  PubMed  Google Scholar 

  5. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27. doi:10.1056/NEJMsa035205.

    Article  CAS  PubMed  Google Scholar 

  6. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2004;8(8):935–49. doi:10.1016/j.gassur.2004.09.046. discussion 49-50.

    Article  Google Scholar 

  7. Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010;101(7):587–92. doi:10.1002/jso.21527.

    Article  CAS  PubMed  Google Scholar 

  8. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson 3rd AB, Casper ES, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. JNCCN. 2012;10(6):703–13.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR. 1997;168(6):1439–43. doi:10.2214/ajr.168.6.9168704.

    Article  CAS  PubMed  Google Scholar 

  10. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2001;5(1):27–35.

    Article  CAS  Google Scholar 

  11. Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, de Wit LT, Verbeek PC, et al. Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg. 1994;81(11):1642–6.

    Article  CAS  PubMed  Google Scholar 

  12. Mollberg N, Rahbari NN, Koch M, Hartwig W, Hoeger Y, Buchler MW, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254(6):882–93. doi:10.1097/SLA.0b013e31823ac299.

    Article  PubMed  Google Scholar 

  13. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045–53. doi:10.1245/s10434-011-2211-4.

    Article  PubMed  Google Scholar 

  14. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77. doi:10.1001/jama.297.3.267.

    Article  CAS  PubMed  Google Scholar 

  15. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. doi:10.1056/NEJMoa032295.

    Article  CAS  PubMed  Google Scholar 

  16. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81. doi:10.1001/jama.2010.1275.

    Article  CAS  PubMed  Google Scholar 

  17. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26. doi:10.1001/jama.299.9.1019.

    Article  CAS  PubMed  Google Scholar 

  18. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17(4):981–90. doi:10.1245/s10434-009-0743-7.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3503–10. doi:10.1200/JCO.2007.15.8469.

    Article  Google Scholar 

  20. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3511–6. doi:10.1200/JCO.2007.15.8782.

    Article  Google Scholar 

  21. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59(12):2006-10.

  22. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903.

    Article  CAS  PubMed  Google Scholar 

  23. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3496–502. doi:10.1200/JCO.2007.15.8634.

    Article  CAS  Google Scholar 

  24. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(21):3487–95. doi:10.1200/JCO.2007.15.8642.

    Article  CAS  Google Scholar 

  25. • Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, et al. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013. doi:10.1002/cncr.28117. This recent study demonstrated improved R0 resection rates with neoadjuvant therapy, but no improvement in overall survival, compared to historical controls.

    Google Scholar 

  26. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705–10.

    Article  CAS  PubMed  Google Scholar 

  27. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. doi:10.1371/journal.pmed.1000267.

    Article  PubMed Central  PubMed  Google Scholar 

  28. • Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26. doi:10.1016/s1470-2045(13)70021-4. This recent study showed potential benefit of capecitabine-based chemoradiation over gemcitabine-based chemoradiation in the secondary endpoint of median overall survival for patients with unresectable pancreatic adenocarcinoma, following induction chemotherapy.

  29. Hammel P, Huguet F, Van Laethem J, Goldstein D, Glimelius B, Artru P et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31 suppl:abstr LBA4003.

  30. •• Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95. doi:10.1245/s10434-013-2886-9. This recent review article discusses the construction of the Alliance Trial.

    Article  PubMed  Google Scholar 

  31. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56. doi:10.1002/cncr.27636.

    Article  PubMed  Google Scholar 

  32. Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2012;16(3):509–17. doi:10.1007/s11605-011-1784-3.

    Article  Google Scholar 

  33. Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. doi:10.1186/1471-2407-12-199.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, et al. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg. 2012;203(2):132–9. doi:10.1016/j.amjsurg.2011.03.008.

    Article  PubMed  Google Scholar 

  35. Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kobayashi T, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepato-Biliary-Pancreat Sci. 2011;18(4):567–74. doi:10.1007/s00534-011-0371-z.

    Article  Google Scholar 

  36. Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27. doi:10.1245/s10434-010-1456-7.

    Article  PubMed  Google Scholar 

  37. Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, et al. Comparison of 1-, 2-, and 3-dimensional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer. GCR. 2011;4(4):128–34.

    PubMed  Google Scholar 

  38. Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80(5):1383–90. doi:10.1016/j.ijrobp.2010.04.058.

    Article  PubMed  Google Scholar 

  39. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB Off J Int Hepato Pancreato Biliary Assoc. 2010;12(1):73–9. doi:10.1111/j.1477-2574.2009.00136.x.

    Article  Google Scholar 

  40. Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832–8. doi:10.1245/s10434-010-1284-9.

    Article  PubMed  Google Scholar 

  41. Turrini O, Viret F, Moureau-Zabotto L, Guiramand J, Moutardier V, Lelong B, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009;35(12):1306–11. doi:10.1016/j.ejso.2009.06.005.

    CAS  Google Scholar 

  42. Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas. 2009;38(3):282–8. doi:10.1097/MPA.0b013e31819438c3.

    Article  CAS  PubMed  Google Scholar 

  43. Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195(3):318–21. doi:10.1016/j.amjsurg.2007.12.017.

    Article  CAS  PubMed  Google Scholar 

  44. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13(9):1201–8. doi:10.1245/s10434-006-9032-x.

    Article  PubMed  Google Scholar 

  45. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119(2):277–84. doi:10.1002/cncr.27736.

    Article  CAS  PubMed  Google Scholar 

  46. • Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park do H, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851–62. doi:10.1016/j.surg.2012.03.010. This study was able to demonstrate excellent R0 rates with neoadjuvant therapy, though patient groups were defined with a proprietary classification system, and not analyzed separately.

    Article  PubMed  Google Scholar 

  47. Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35(7):1580–9. doi:10.1007/s00268-011-1113-8.

    Article  PubMed  Google Scholar 

  48. Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery. 2011;149(3):311–20. doi:10.1016/j.surg.2010.07.048.

    Article  PubMed  Google Scholar 

  49. Small Jr W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(6):942–7. doi:10.1200/JCO.2007.13.9014.

    Article  CAS  Google Scholar 

  50. Pipas JM, Barth Jr RJ, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, et al. Docetaxel/gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2005;12(12):995–1004. doi:10.1245/ASO.2005.04.503.

    Article  PubMed  Google Scholar 

  51. Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P, Siewert JR, et al. Sequential and/or concurrent hypofractionated radiotherapy and concurrent chemotherapy in neoadjuvant treatment of advanced adenocarcinoma of the pancreas. Outcome and patterns of failure. Hepato-Gastroenterology. 2004;51(60):1842–6.

    PubMed  Google Scholar 

  52. • Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013. doi:10.1245/s10434-013-3129-9. This study of neoadjuvant therapy demonstrated excellent R0 and survival rates, though the population was defined with a proprietary system including less threatening anatomy than most widely-accepted systems.

    PubMed  Google Scholar 

  53. Jinkins LJ, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, et al. Current trends in preoperative biliary stenting in patients with pancreatic cancer. Surgery. 2013;154(2):179–89. doi:10.1016/j.surg.2013.03.016.

    Article  PubMed  Google Scholar 

  54. Ross WA, Wasan SM, Evans DB, Wolff RA, Trapani LV, Staerkel GA, et al. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc. 2008;68(3):461–6. doi:10.1016/j.gie.2007.11.033.

    Article  PubMed  Google Scholar 

  55. Gress F, Michael H, Gelrud D, Patel P, Gottlieb K, Singh F, et al. EUS-guided fine-needle aspiration of the pancreas: evaluation of pancreatitis as a complication. Gastrointest Endosc. 2002;56(6):864–7. doi:10.1067/mge.2002.129602.

    Article  PubMed  Google Scholar 

  56. Mullen JT, Lee JH, Gomez HF, Ross WA, Fukami N, Wolff RA, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2005;9(8):1094–104. doi:10.1016/j.gassur.2005.08.006. discussion 104-5.

    Article  Google Scholar 

  57. Kozarek R. Role of preoperative palliation of jaundice in pancreatic cancer. J Hepato-Biliary-Pancreat Sci. 2013. doi:10.1007/s00534-013-0612-4.

    Google Scholar 

  58. Lee JH, Krishna SG, Singh A, Ladha HS, Slack RS, Ramireddy S, et al. Comparison of the utility of covered metal stents versus uncovered metal stents in the management of malignant biliary strictures in 749 patients. Gastrointest Endosc. 2013;78(2):312–24. doi:10.1016/j.gie.2013.02.032.

    Article  PubMed  Google Scholar 

  59. Bruno MJ, Haverkort EB, Tijssen GP, Tytgat GN, van Leeuwen DJ. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42(1):92–6.

    Article  CAS  PubMed  Google Scholar 

  60. Gooden HM, White KJ. Pancreatic cancer and supportive care–pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2013;21(7):1835–41. doi:10.1007/s00520-013-1729-3.

    CAS  Google Scholar 

  61. Shinkawa H, Takemura S, Uenishi T, Sakae M, Ohata K, Urata Y, et al. Nutritional risk index as an independent predictive factor for the development of surgical site infection after pancreaticoduodenectomy. Surg Today. 2013;43(3):276–83. doi:10.1007/s00595-012-0350-2.

    Article  PubMed  Google Scholar 

  62. La Torre M, Ziparo V, Nigri G, Cavallini M, Balducci G, Ramacciato G. Malnutrition and pancreatic surgery: prevalence and outcomes. J Surg Oncol. 2013;107(7):702–8. doi:10.1002/jso.23304.

    Article  PubMed  Google Scholar 

  63. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. doi:10.1056/NEJMoa1011923.

    Article  CAS  PubMed  Google Scholar 

  64. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi:10.1056/NEJMoa1304369.

    Article  Google Scholar 

  65. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350–3.

    Article  CAS  PubMed  Google Scholar 

  66. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(14):4674–9. doi:10.1158/1078-0432.CCR-09-0227.

    Article  CAS  Google Scholar 

  67. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(11):1806–13. doi:10.1200/JCO.2008.17.7188.

    Article  CAS  Google Scholar 

  68. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3. doi:10.1038/nm.2344.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828–33. doi:10.1097/CJI.0b013e3181eec14c.

    Article  CAS  PubMed  Google Scholar 

  70. Niu L, Chen J, He L, Liao M, Yuan Y, Zeng J, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013. doi:10.1097/MPA.0b013e3182965dde.

    Google Scholar 

  71. DeVito NC, Saif MW. Advances in immunotherapy for pancreatic cancer: 2013. JOP. 2013;14(4):347–53. doi:10.6092/1590-8577/1646.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Daniel M. Halperin declares that he has no conflict of interest.

Gauri R. Varadhachary is a consultant for and has received honoraria from Celgene.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Daniel M. Halperin & Gauri R. Varadhachary

Authors
  1. Daniel M. Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gauri R. Varadhachary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gauri R. Varadhachary.

Additional information

This article is part of the Topical Collection on Gastrointestinal Cancers

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halperin, D.M., Varadhachary, G.R. Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?. Curr Oncol Rep 16, 366 (2014). https://doi.org/10.1007/s11912-013-0366-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-013-0366-9

Keywords

Search

Navigation